Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Shared Immune Pathways Linking Skin, Gut, and Metabolic Health in Inflammatory Skin Disease
Description
The lecture explains that inflammatory skin diseases are not limited to the skin but are linked to systemic inflammation, gut dysfunction, and metabolic disease through shared immune pathways. It reviews the gut-skin axis, emphasizing how microbiome imbalance (dysbiosis) can reduce anti-inflammatory short-chain fatty acids, weaken barriers, and promote pro-inflammatory T-cell responses such as Th17. It highlights atopic dermatitis and the dual allergen hypothesis, the rising recognition of eosinophilic esophagitis, and the need to ask about dysphagia, food impaction, refractory heartburn, feeding problems, and related behaviors, with GI referral and consideration of dupilumab when appropriate. For inflammatory bowel disease, the talk reviews Crohn’s disease and ulcerative colitis, their extraintestinal skin manifestations, and how to recognize cutaneous Crohn’s, perianal disease, metastatic Crohn’s, erythema nodosum, and the overlap with hidradenitis suppurativa. It emphasizes fecal calprotectin as a practical screening test and advises caution or avoidance of IL-17 inhibitors in patients with IBD. The presentation also covers TNF-inhibitor–induced dermatitis, noting that management may require adding or switching systemic therapy based on the skin phenotype. Finally, it discusses how obesity and metabolic syndrome drive inflammation in psoriasis, hidradenitis suppurativa, and atopic dermatitis through adipose-derived cytokines and adipokines, and reviews screening for BMI, blood pressure, lipids, and glucose, along with the potential role of metformin and GLP-1 therapies. The central message is that dermatologists play a key role in identifying comorbidities, coordinating care, and improving outcomes through interdisciplinary management.
View moreConclusions
- Inflammatory skin diseases appear to be systemic disorders rather than isolated skin conditions, with shared immune pathways linking the skin, gut, and adipose tissue.
- Gut dysbiosis and impaired barrier function can promote systemic inflammation that worsens or helps drive inflammatory skin disease and related comorbidities.
- Atopic dermatitis is closely linked to eosinophilic gastrointestinal disease, suggesting that stronger control of skin disease may help reduce progression along the atopic march.
- Dermatologists should screen patients with atopic dermatitis, hidradenitis suppurativa, and inflammatory bowel disease for relevant gastrointestinal symptoms and consider fecal calprotectin or GI referral when indicated.
- Cutaneous Crohn’s disease and other extraintestinal IBD manifestations are common enough to require active recognition, even when bowel symptoms are mild or absent.
- Perianal hidradenitis suppurativa and perianal Crohn’s disease can overlap clinically, but features like comedones and tunnels favor HS, while knife-like fissures, genital edema, fistulas, and skin tags raise concern for Crohn’s disease.
- IL-17 inhibitors should generally be avoided in patients with inflammatory bowel disease because they may worsen or trigger IBD.
- TNF-inhibitor–associated dermatitis is a real paradoxical reaction that often requires topical therapy plus switching or adding another systemic agent rather than simply changing to a different TNF inhibitor.
- Obesity and metabolic syndrome are strongly associated with psoriasis, hidradenitis suppurativa, and atopic dermatitis, and worsening metabolic health can worsen skin disease severity.
- Addressing metabolic dysfunction with weight management, exercise, diet, primary care collaboration, and selected therapies such as metformin or GLP-1 agents may improve both systemic health and skin outcomes.
- The dermatologist has an important role in identifying comorbid disease, guiding treatment selection, and coordinating interdisciplinary care that improves quality of life and overall outcomes.
- Souto-Silva MV et al. The cytokine-skin barrier axis in health and disease. Cytokine Growth Factor Rev. 2025.#10.1016/j.cytogfr.2025.12.009
- Constantin C et al. Insights into Nutritional Strategies in Psoriasis. Nutrients. 2023.#10.3390/nu15163528
- Hawkes JE et al. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017.#10.1016/j.jaci.2017.07.004
- Sabat R et al. Hidradenitis suppurativa. Lancet. 2025.
- Garg A, Krueger JG. Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies. Br J Dermatol. 2022.#10.1111/bjd.21275
- Silverberg 2019
- Nakajima 2024
- De Pessemier
- Holmes
- Haidar I. et al. Beyond the Skin: Exploring the Gut-Skin Axis in Chronic Spontaneous Urticaria and Other Inflammatory Skin Diseases. Biomedicines, 2025.#10.3390/biomedicines13082014
- Antonelli E et al. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med. 2021.#10.3390/jcm10020364
- Ickrath F et al. Metastatic Crohn’s disease: an underestimated entity. J Dtsch Dermatol Ges. 2021.#10.1111/ddg.14447
- D’Amico
- Waugh
- Walsham
- Beilby J. 2004 review on the definition of metabolic syndrome.
- Xia J et al. Metabolic syndrome and dermatological diseases: association and treatment. Nutr Metab (Lond). 2025.#10.1186/s12986-025-00924-1
- Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018.#10.1111/exd.13467
- Secchiero P et al. Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota. Int J Mol Sci. 2024.#10.3390/ijms25158098
- Hu Y et al. Metabolic Syndrome and Skin Diseases. Front. Endocrinol. 2019.#10.3389/fendo.2019.00788
- Cui et al. Nature Reviews Endocrinology 2017.
- Dodington et al. Trends in Endocrinology & Metabolism 2018.
- Ibba L et al. Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: a monocentric retrospective study. Clin Exp Dermatol. 2025.#10.1093/ced/llaf144
- Elmets CA et al.
- Li Z et al.
- Garg A. et al., Journal of the American Academy of Dermatology, 2022.
- Dagenet, Lee, Sayed, Hsiao, Shi. Am J Clin Dermatol. 2025.
- Rizvi et al. Diabetes Metab Syndr Obes. 2022.
- Pantazopoulos et al. 2025 review on metformin’s therapeutic potential in the skin.
- Koseki M, Cices A, et al. Association between inflammatory bowel disease and hidradenitis suppurativa: a single-center retrospective study. Gastroenterology, 2025.#10.1053/j.gastro.2025.01.093
- Yamanaka-Takaichi MLE et al. Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa. Int J Dermatol. 2024.#10.1111/ijd.17498
- Burisch et al. 2020.
- Yamada et al. 2019.
- Deng et al. 2023.
- Hu et al. 2025.
- Waugh N et al. Health Technol Assess. 2013.
- Phan K et al.
- Koseko M et al.
- Amatore F, Colombel JF, Delaporte E.
- Hindryckx et al., 2017.
- Yang X et al. Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives. Mol Biomed. 2026.#10.1186/s43556-025-00395-z
- Faggiani et al. Biomedicines, 2024.
- Tie Y et al. Gut Microbes, 2023.
- Souto-Silva MV et al. The cytokine-skin barrier axis in health and disease. Cytokine Growth Factor Rev. 2025.#10.1016/j.cytogfr.2025.12.009